Two subsidiaries of the drugmaker Johnson & Johnson agreed to pay more than $81 million to settle a case accusing them of illegally promoting the epilepsy drug Topamax for psychiatric conditions, the Department of Justice announced Thursday.
Pharmaceutical companies are not allowed to promote drugs for uses that have not been approved by the Food and Drug Administration, a practice called off-label marketing. But the DOJ says one Johnson & Johnson subsidiary promoted Topamax for off-label uses through a “Doctor for a Day” program, which hired phyicians to accompany pharmaceutical salespeople on calls to other doctors’ offices and speak at meetings about unapproved uses for Topamax.
Topamax was a huge moneymaker for the pharmaceutical giant; its sales peaked at $2.7 billion in 2008 before being undercut by generic competition in 2009, the Associated Press reports.
A Johnson & Johnson subsidiary pleaded guilty to a single count of misdemeanor violation of the Food, Drug and Cosmetic Act and agreed to pay a $6.1 million fine in connection to the charges but denied any other wrongdoing.

